Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 8, Issue 22

November 26 2024

In this Issue

INSIDE BLOOD ADVANCES
ADVANCES VIEWPOINT
CLINICAL TRIALS AND OBSERVATIONS
GENE THERAPY
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
RESEARCH LETTERS
COMMENTARIES
LETTERS TO THE EDITOR
RESPONSE
ERRATA

INSIDE BLOOD ADVANCES

A contemporary downtrend in chronic GVHD?
Clinical Trials & Observations

Najla El Jurdi,Steven Z. Pavletic

View Articletitled, A contemporary downtrend in chronic GVHD?

ADVANCES VIEWPOINT

Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice

Vincenzo La Mura,Vincenzo Cardinale,Raimondo De Cristofaro,Adriano De Santis,Giovanni Di Minno,Luca Fabris,Fabio Marra,Filomena Morisco,Flora Peyvandi,Maurizio Pompili,Cristina Santoro,Ezio Zanon,Giancarlo Castaman

View Articletitled, Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice

CLINICAL TRIALS AND OBSERVATIONS

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis
Clinical Trials & Observations

Chenyu Lin,Anand A. Patel,Dezheng Huo,Theodore Karrison,Koen van Besien,John Godwin,Dorie Sher,Howie Weiner,Margaret Green,James L. Wade, III,Rebecca Klisovic,Maria R. Baer,Richard A. Larson,Wendy Stock,Olatoyosi Odenike

View Articletitled, A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis

Supplemental data

Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Clinical Trials & Observations

Amitkumar Mehta,Leslie Popplewell,Graham P. Collins,Sonali M. Smith,Ian W. Flinn,Nancy L. Bartlett,Nilanjan Ghosh,Gal Hacohen-Kleiman,Yanan Huo,Linda Su-Feher,Camille Renard,Ranjana Advani,Mark Roschewski

View Articletitled, Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial

Supplemental data

Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Clinical Trials & Observations

Joseph E. Maakaron,Adam Asch,Leslie Popplewell,Graham P. Collins,Ian W. Flinn,Nilanjan Ghosh,Colm Keane,Matthew Ku,Amitkumar Mehta,Mark Roschewski,Gal Hacohen-Kleiman,Yanan Huo,Yi Zhang,Camille Renard,Sonali M. Smith,Ranjana Advani

View Articletitled, Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma

Supplemental data

Psychological burden and depressive symptoms in caregivers of hemato-oncological patients: the role of medical visits
Clinical Trials & Observations

Ali Abed Al Wahad,Roni Elran-Barak,Marina Furer,Gihan Abu Kamir,Netanel A. Horowitz

View Articletitled, Psychological burden and depressive symptoms in caregivers of hemato-oncological patients: the role of medical visits

GENE THERAPY

UM171 enhances fitness and engraftment of gene-modified hematopoietic stem cells from patients with sickle cell disease

Boya Liu,Denise Klatt,Yu Zhou,John P. Manis,Guy Sauvageau,Danilo Pellin,Christian Brendel,David A. Williams

View Articletitled, UM171 enhances fitness and engraftment of gene-modified hematopoietic stem cells from patients with sickle cell disease

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Platelet Ido1 expression is induced during Plasmodium yoelii infection, altering plasma tryptophan metabolites

Sara K. Blick-Nitko,Sara K. Ture,Xenia L. Schafer,Joshua C. Munger,Alison C. Livada,Chen Li,Preeti Maurya,Matthew T. Rondina,Craig N. Morrell

View Articletitled, Platelet Ido1 expression is induced during Plasmodium yoelii infection, altering plasma tryptophan metabolites

Supplemental data

LYMPHOID NEOPLASIA

Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL

Sehui Kim,Hyein Jeong,Hyun Kyung Ahn,Bogyeong Han,Ki-Chang Lee,Young Keun Song,Sojung Lim,Jeemin Yim,Jaemoon Koh,Yoon Kyung Jeon

View Articletitled, Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL

Supplemental data

Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax

Yannis K. Valtis,David Nemirovsky,Andriy Derkach,Saumya Sharan,Charlene Kabel,Ricardo Ortiz,Meghan C. Thompson,Lindsey E. Roeker,Mark B. Geyer

View Articletitled, Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax

Supplemental data

MYELOID NEOPLASIA

Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms

Neval Ozkaya,Sarah Melloul Benizri,Girish Venkataraman,Laszlo J. Karai,Sylvie Fraitag,Jérôme Razanamahery,Stefania Pittaluga,Maxime Battistella,Svetlana Pack,François Le Pelletier,Liqiang Xi,Anne Moreau,Ina Lee,Zofia Hélias-Rodzewicz,Jean Donadieu,Julien Haroche,Mark Raffeld,Elaine S. Jaffe,Jean-François Emile

View Articletitled, Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

In vivo silencing of intestinal DMT1 mitigates iron loading in β-thalassemia intermedia (Hbb^th3/+) mice

Yang Yu,Regina R. Woloshun,Jennifer K. Lee,Pearl O. Ebea-Ugwuanyi,Jacob S. Shine,Sean Zhu,Yue He,James F. Collins

View Articletitled, In vivo silencing of intestinal DMT1 mitigates iron loading in β-thalassemia intermedia (Hbbth3/+) mice

Supplemental data

THROMBOSIS AND HEMOSTASIS

Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments

Halina H. L. Leung,Zohra Ahmadi,Brendan Lee,John Casey,Sumita Ratnasingam,Steven E. McKenzie,Jose Perdomo,Beng H. Chong

View Articletitled, Antithrombotic efficacy and bleeding risks of vaccine-induced immune thrombotic thrombocytopenia treatments

Supplemental data

Predictors of liver disease outcomes in individuals with hemophilia and HCV infection

Ilias Christodoulou,Scott Rothenberger,Margaret V. Ragni

View Articletitled, Predictors of liver disease outcomes in individuals with hemophilia and HCV infection

Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial

Marisol Betensky,Maua Mosha,Cristina Tarango,Anupam Verma,Rukhmi Bhat,Nicole E. Kucine,Taizo Nakano,Charles Nakar,Gary Woods,Ernest Amankwah,Leonardo R. Brandão,Sam Schulman,Neil A. Goldenberg

View Articletitled, Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial

Supplemental data

Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort

Jacqueline N. Poston,Cassandra Bryan,Annette von Drygalski,Kadhim Al Banaa,Jenny Y. Zhou,Aric Parnes,Evan C. Chen,Osman Khan,Patrick Ellsworth,Lorraine Cafuir,Christopher Walsh,Miguel A. Escobar,James F. Wu,Lynn M. Malec,Craig M. Kessler,Maissaa Janbain,Rebecca Kruse-Jarres

View Articletitled, Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort

Supplemental data

Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing

Xiao-Qin Liu,Zi-Ran Li,Chen-Yu Wang,Zheng Jiao

View Articletitled, Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing

Supplemental data

TRANSPLANTATION

Decreasing chronic graft-versus-host disease rates in all populations
Clinical Trials & Observations

Paul A. Carpenter,Ted A. Gooley,Julie Boiko,Catherine J. Lee,Lauri M. Burroughs,Rohtesh Mehta,Rachel B. Salit,Neel S. Bhatt,Elizabeth Krakow,Ann E. Dahlberg,Albert C. Yeh,Corinne N. Summers,Masumi Ueda Oshima,Effie W. Petersdorf,Phuong Vo,Laura Connelly-Smith,Stephanie J. Lee

View Articletitled, Decreasing chronic graft-versus-host disease rates in all populations

Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children

Reem Elfeky,Natalia Builes,Rachel Pearce,Soumya Kania,Zohreh Nademi,Giovanna Lucchini,Robert Chiesa,Persis Amrolia,Mohamed Sorror,Paul Veys,Kanchan Rao

View Articletitled, Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children

Supplemental data

RESEARCH LETTERS

Evaluation of hemoglobin S percent threshold to prevent severe pain events: a secondary analysis of the SIT trial

Jose Mejias,Alejandro R. Gonzalez-Barreto,Mark Rodeghier,Michael R. DeBaun

View Articletitled, Evaluation of hemoglobin S percent threshold to prevent severe pain events: a secondary analysis of the SIT trial

Supplemental data

Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells

Mehmet H. Kocoglu,Tim Luetkens,Jacqueline T. Bork,John Baddley,Destiny Omili,Etse Gebru,Rediet Mulatu,Daniel Yamoah,Thierry Iraguha,Xiaoxuan Fan,Patricia Lesho,Mohammad Yousaf,Jillian M. Baker,Kenneth A. Dietze,Kim G. Hankey,Ashraf Badros,Jean A. Yared,Aaron P. Rapoport,Nancy M. Hardy,Djordje Atanackovic

View Articletitled, Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells

Supplemental data

COMMENTARIES

Defying the odds: 30 years in AL amyloidosis research—recent barriers to clinical trial enrollment
Clinical Trials & Observations

Vaishali Sanchorawala,Bruna Barroso,Anthony Shelton,Elise Goetz,Lisa Mendelson,Tracy Joshi,Natasha Burke,J. Mark Sloan,Andrew Staron

View Articletitled, Defying the odds: 30 years in AL amyloidosis research—recent barriers to clinical trial enrollment

Diabetes mellitus, metformin, and the risk of MPN

Ivan Krecak,Sanja Klobucar,Josipa Budimir,Marko Skelin,Marko Lucijanic

View Articletitled, Diabetes mellitus, metformin, and the risk of MPN

LETTERS TO THE EDITOR

Improving infection reporting in hematology treatment trials
Clinical Trials & Observations

Benjamin W. Teh,Gemma K. Reynolds,Malgorzata Mikulska,Nicolas J. Mueller,Monica A. Slavin

View Articletitled, Improving infection reporting in hematology treatment trials

Improving reporting of infection events in clinical trials
Clinical Trials & Observations

Heinz Ludwig,Nikhil C. Munshi,Evangelos Terpos,Noopur Raje,Philippe Moreau,Ajay Nooka

View Articletitled, Improving reporting of infection events in clinical trials

RESPONSE

The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes
Clinical Trials & Observations

Daniel Tuyet Kristensen,Andreas Kiesbye Øvlisen,Tarec Christoffer El-Galaly,Anne Stidsholt Roug

View Articletitled, The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes

ERRATA

Imus PH, Pasca S, Tsai H-L, et al. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024;8(14):3849-3858.

View Articletitled, Imus PH, Pasca S, Tsai H-L, et al. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024;8(14):3849-3858.

Glisovic-Aplenc T, Diorio C, Chukinas JA, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418-4430.

View Articletitled, Glisovic-Aplenc T, Diorio C, Chukinas JA, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418-4430.

Sewastianik T, Jiang M, Sukhdeo K, et al. Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Adv. 2017;1(25):2361-2374.

View Articletitled, Sewastianik T, Jiang M, Sukhdeo K, et al. Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Adv. 2017;1(25):2361-2374.

Supplemental data

Cover Image

Cover Image

Hematoxylin and eosin–stained lung tissue from a mouse with vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with a direct FcγRIIa inhibitor. The absence of clots in these mice suggests that blocking FcγRIIa is effective in preventing VITT-induced thrombus formation in vivo. See the article by Leung et al.

All Issues

Advertisement intended for health care professionals

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Time to revisit reduced-dose radiotherapy for PCNSL?

Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.

Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Issue Archive

Table of Contents

INSIDE BLOOD ADVANCES

A contemporary downtrend in chronic GVHD? Clinical Trials & Observations

ADVANCES VIEWPOINT

CLINICAL TRIALS AND OBSERVATIONS

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis Clinical Trials & Observations

Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial Clinical Trials & Observations

Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma Clinical Trials & Observations

Psychological burden and depressive symptoms in caregivers of hemato-oncological patients: the role of medical visits Clinical Trials & Observations

GENE THERAPY

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

Decreasing chronic graft-versus-host disease rates in all populations Clinical Trials & Observations

RESEARCH LETTERS

COMMENTARIES

Defying the odds: 30 years in AL amyloidosis research—recent barriers to clinical trial enrollment Clinical Trials & Observations

LETTERS TO THE EDITOR

Improving infection reporting in hematology treatment trials Clinical Trials & Observations

Improving reporting of infection events in clinical trials Clinical Trials & Observations

RESPONSE

The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes Clinical Trials & Observations

ERRATA

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

A contemporary downtrend in chronic GVHD?
Clinical Trials & Observations

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis
Clinical Trials & Observations

Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial
Clinical Trials & Observations

Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Clinical Trials & Observations

Psychological burden and depressive symptoms in caregivers of hemato-oncological patients: the role of medical visits
Clinical Trials & Observations

Decreasing chronic graft-versus-host disease rates in all populations
Clinical Trials & Observations

Defying the odds: 30 years in AL amyloidosis research—recent barriers to clinical trial enrollment
Clinical Trials & Observations

Improving infection reporting in hematology treatment trials
Clinical Trials & Observations

Improving reporting of infection events in clinical trials
Clinical Trials & Observations

The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes
Clinical Trials & Observations